KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Capital Expenditures (2016 - 2025)

Merck (MRK) has disclosed Capital Expenditures for 17 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 10.25% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 billion through Dec 2025, up 21.95% year-over-year, with the annual reading at $4.1 billion for FY2025, 21.95% up from the prior year.
  • Capital Expenditures for Q4 2025 was $1.0 billion at Merck, up from $987.0 million in the prior quarter.
  • The five-year high for Capital Expenditures was $1.3 billion in Q1 2025, with the low at $764.0 million in Q2 2025.
  • Average Capital Expenditures over 5 years is $1.0 billion, with a median of $988.0 million recorded in 2023.
  • The sharpest move saw Capital Expenditures surged 288.08% in 2021, then fell 19.89% in 2023.
  • Over 5 years, Capital Expenditures stood at $1.2 billion in 2021, then fell by 4.88% to $1.1 billion in 2022, then dropped by 13.93% to $989.0 million in 2023, then fell by 5.26% to $937.0 million in 2024, then rose by 10.25% to $1.0 billion in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1.0 billion, $987.0 million, and $764.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.